Correspondence 0001104659-23-095129 from Immunome Inc. (IMNM) (CIK 0001472012) (IMNM)
Immunome Inc. (IMNM) (CIK 0001472012)
Date: Aug. 25, 2023 · CIK: 0001472012 · Accession: 0001104659-23-095129
AI Filing Summary & Sentiment
File numbers found in text: 333-273792
Letter
Immunome, Inc.
665 Stockton Drive, Suite 300
Exton, Pennsylvania 19341
August 25, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
RE: Immunome, Inc.
Registration Statement on Form S-4 File No. 333-273792
Request for Acceleration of Effectiveness
Ladies and Gentlemen:
In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended, Immunome, Inc. (the “Company”) hereby requests acceleration of the effective date of the Registration Statement on Form S-4 (File No. 333-273792), as amended (the “Registration Statement”), so that it may become effective at 9:00 a.m., Washington, D.C. time, on August 28, 2023, or as soon as possible thereafter.
The Company hereby authorizes Daniel A. Bagliebter, Esq. of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. to orally modify or withdraw this request for acceleration.
The Company respectfully requests that it be notified of such effectiveness by a telephone call to Attorney Bagliebter at (212) 692-6856 and that such effectiveness also be confirmed in writing. Any questions regarding this request may be addressed to Attorney Bagliebter.
Very truly yours,
IMMUNOME, INC.
Show Raw Text
CORRESP
1
filename1.htm
Immunome, Inc.
665 Stockton Drive, Suite 300
Exton, Pennsylvania 19341
August 25, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
RE: Immunome, Inc.
Registration Statement on Form S-4 File
No. 333-273792
Request for Acceleration of Effectiveness
Ladies and Gentlemen:
In accordance with Rule 461 promulgated under
the Securities Act of 1933, as amended, Immunome, Inc. (the “Company”) hereby requests acceleration of the
effective date of the Registration Statement on Form S-4 (File No. 333-273792), as amended (the “Registration Statement”),
so that it may become effective at 9:00 a.m., Washington, D.C. time, on August 28, 2023, or as soon as possible thereafter.
The Company hereby authorizes Daniel A. Bagliebter, Esq.
of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. to orally modify or withdraw this request for acceleration.
The Company respectfully requests that it be notified
of such effectiveness by a telephone call to Attorney Bagliebter at (212) 692-6856 and that such effectiveness also be confirmed in writing.
Any questions regarding this request may be addressed to Attorney Bagliebter.
Very truly yours,
IMMUNOME, INC.
/s/ Purnanand D. Sarma, Ph.D
Purnanand D. Sarma, Ph.D.
President and Chief Executive Officer
cc: Immunome, Inc.
Sandra Stoneman, Esq., Chief Legal Officer
and General Counsel
Mintz, Levin, Cohn, Ferris, Glovsky and
Popeo, P.C.
Daniel A. Bagliebter, Esq.
Cooley LLP
Thomas Coll, Esq.
Barbara Borden, Esq.
Carlos Ramirez, Esq.